Title |
Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?
|
---|---|
Published in |
Annals of Oncology, October 2014
|
DOI | 10.1093/annonc/mdu480 |
Pubmed ID | |
Authors |
M Ignatiadis, S-J Dawson |
Abstract |
Next-generation sequencing studies have provided further evidence to support the notion that cancer is a disease characterized by Darwinian evolution. Today, we often fail to capture this evolution and treatment decisions, even in the metastatic setting, are often based on analysis of primary tumor diagnosed years ago. Currently, this is considered a major reason for treatment failures in cancer care. Recent technological advances in the detection and characterization of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) might address this and allow for treatment tailoring based on real-time monitoring of tumor evolution. In this review, we summarize the most important recent findings in the field, focusing on challenges and opportunities in moving these tools forward in clinical practice. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 5 | 26% |
Spain | 2 | 11% |
Germany | 1 | 5% |
Australia | 1 | 5% |
Belgium | 1 | 5% |
Unknown | 9 | 47% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 9 | 47% |
Practitioners (doctors, other healthcare professionals) | 6 | 32% |
Scientists | 4 | 21% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | <1% |
Spain | 2 | <1% |
Sweden | 2 | <1% |
Israel | 1 | <1% |
United Kingdom | 1 | <1% |
France | 1 | <1% |
Romania | 1 | <1% |
Ireland | 1 | <1% |
Mexico | 1 | <1% |
Other | 1 | <1% |
Unknown | 258 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 57 | 21% |
Student > Ph. D. Student | 43 | 16% |
Student > Bachelor | 27 | 10% |
Other | 25 | 9% |
Student > Master | 23 | 8% |
Other | 51 | 19% |
Unknown | 45 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 79 | 29% |
Biochemistry, Genetics and Molecular Biology | 52 | 19% |
Agricultural and Biological Sciences | 50 | 18% |
Engineering | 10 | 4% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 1% |
Other | 18 | 7% |
Unknown | 58 | 21% |